Tag: Hormones: Misc.
Effect of COVID-19 on Breast Cancer Treatment Examined
More patients with estrogen receptor-positive, HER2-negative breast cancer treated with neoadjuvant endocrine therapy due to COVID-19
Fertility Concerns Impact Treatment Decisions in Breast Cancer
One-third of young women with breast cancer indicated that fertility concerns affected decisions relating to endocrine therapy
AHA Offers Guidance for CVD Risk in Breast, Prostate Cancer
Patients with breast, prostate cancer who are receiving hormonal therapy more likely to develop cardiovascular risk factors
Gender-Affirming Hormone Therapy Tied to Systolic BP Changes
Within two to four months, increases, decreases in systolic BP seen in transmasculine, transfeminine adults, respectively
Study Explores Oxytocin Use in Active Phase of Induced Labor
Discontinuation of oxytocin may lead to small increase in rate of cesarean section, decrease in fetal heart rate abnormalities
Prolonged High-Dose Cyproterone Acetate Use Linked to Risk for Meningioma
Risk increased for meningiomas treated with surgery or radiotherapy; risk decreased after discontinuation of treatment
Primary Aldosteronism Testing Rare in Treatment-Resistant HTN
Testing correlated with increased likelihood of initiation of MRA therapy and with better BP control over time
Hormonal Contraceptives Linked to Decline in Asthma Exacerbation
Risk reduced with previous and current use of any and combined hormonal contraceptives, not with progestogen-only use
Lack of Insurance Tied to Non-Rx Hormone Use in Transgender Adults
Authors say insurance barrier poses risks to safety, health, and well-being
